Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Moderate Asthma

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44393   clinical trials with a EudraCT protocol, of which   7405   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    391 result(s) found for: Moderate Asthma. Displaying page 7 of 20.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next» Last»»
    EudraCT Number: 2011-005512-28 Sponsor Protocol Number: 205.443 Start Date*: 2012-10-04
    Sponsor Name:Boehringer Ingelheim
    Full Title: A phase II/III, randomised, double-blind, placebo-controlled, parallel group trial to evaluate safety and efficacy of tiotropium inhalation solution (2.5 µg and 5 µg) administered once daily in the...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed) LT (Completed) LV (Completed) FI (Completed) DE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2005-006077-27 Sponsor Protocol Number: BS559 Start Date*: 2006-06-26
    Sponsor Name:Merck Generics
    Full Title: A MULTICENTRE, DOUBLE-BLIND, DOUBLE-DUMMY, RANDOMISED, PARALLEL-GROUP STUDY TO DETERMINE THE THERAPEUTIC EQUIVALENCE BETWEEN FLUTICASONE PROPIONATE, 100 µg TWICE DAILY DELIVERED VIA A PRESSURISED M...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    8.1 10003555 LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: CZ (Completed) SK (Completed) HU (Completed) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-005306-37 Sponsor Protocol Number: D3741C00003 Start Date*: 2015-05-27
    Sponsor Name:AstraZeneca AB
    Full Title: A randomized, double-blind, multiple dosing (14 days), placebo-controlled, incomplete block crossover, multi-center study to assess efficacy and safety of three dose levels of AZD7594, given once d...
    Medical condition: Patients with mild to moderate asthma
    Disease: Version SOC Term Classification Code Term Level
    18.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2010-021093-11 Sponsor Protocol Number: 205.444 Start Date*: 2010-11-13
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: A Phase III randomised, double blind, placebo-controlled, parallel group study to assess the efficacy and safety over 48 weeks of orally inhaled Tiotropium bromide (2.5 µg and 5 µg once daily ) del...
    Medical condition: moderate persistent asthma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: LV (Completed) HU (Completed) ES (Completed) SK (Completed) IT (Prematurely Ended) DE (Completed) NO (Ongoing) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-001483-29 Sponsor Protocol Number: CCD-1202-PR-0080 Start Date*: 2012-08-08
    Sponsor Name:Chiesi Farmaceutici S.p.A.
    Full Title: A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, THREE-WAY CROSSOVER STUDY TO EVALUATE THE EFFICACY AFTER ALLERGEN CHALLENGE, SAFETY, AND TOLERABILITY OF TWO DOSES OF INHALED CHF6001 DPI AFTER 9 DAY...
    Medical condition: asthma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-013705-34 Sponsor Protocol Number: D0540C00004 Start Date*: 2009-10-05
    Sponsor Name:AstraZeneca AB
    Full Title: A double-blind, placebo controlled, randomised, parallel group, single centre, phase IIa study to investigate the efficacy, tolerability and safety of 8 doses of AZD8848 administered intranasally o...
    Medical condition: Allergic Asthma
    Disease: Version SOC Term Classification Code Term Level
    12.0 10001705 Allergic asthma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-006013-24 Sponsor Protocol Number: OC000459/012/08 Start Date*: 2009-03-25
    Sponsor Name:Oxagen Ltd.
    Full Title: Dose Finding Study in Patients with Mild to Moderate Persistent Asthma: A Parallel Group, Randomised, Placebo Controlled, Double Blind Assessment of Oral OC000459 Dosed at Three Dose Schedules for ...
    Medical condition: Mild to moderate persistent asthma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003553 Asthma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2021-003338-35 Sponsor Protocol Number: D7552C00001 Start Date*: 2022-06-06
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase 2, Randomised, Double-Blind, Placebo-Controlled Study to Assess Efficacy and Safety of Multiple Dose Levels of Atuliflapon Given Orally Once Daily for Twelve Weeks in Adults with Moderate-t...
    Medical condition: Moderate-to-Severe Uncontrolled Asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) PL (Trial now transitioned) HU (Trial now transitioned) BG (Trial now transitioned) SI (Trial now transitioned) SK (Trial now transitioned) NL (Trial now transitioned) IT (Prematurely Ended) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-003663-35 Sponsor Protocol Number: PBF-680CT-05 Start Date*: 2018-06-13
    Sponsor Name:Palobiofarma S.L
    Full Title: A phase II, double-blind, randomized, parallel-group, placebocontrolled multi-center study to investigate the effect of the adenosine A1 receptor antagonist PBF-680 on forced expiratory volume in 1...
    Medical condition: patients with mild-to-moderate persistent atopic asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10003638 Atopic asthma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-000865-29 Sponsor Protocol Number: C38072-AS-30025 Start Date*: 2015-10-01
    Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc.
    Full Title: A 52-Week Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Reslizumab 110 mg Fixed, Subcutaneous Dosing in Patients with Uncontrolled Asthma and Elevated Blood Eosinophils
    Medical condition: Uncontrolled Asthma & elevated blood Eosinophils
    Disease: Version SOC Term Classification Code Term Level
    19.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) ES (Prematurely Ended) HU (Prematurely Ended) BE (Completed) PL (Prematurely Ended) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-003395-40 Sponsor Protocol Number: O-AV Start Date*: 2012-10-04
    Sponsor Name:Watson Laboratories, Inc.
    Full Title: Double-blind, masked, randomized, three period crossover study to evaluate the changes in exhaled nitric oxide (eNO) following treatment with fluticasone propionate MDI Aerosol in patients with chr...
    Medical condition: Chronic mild to moderate persistent asthma
    Disease: Version SOC Term Classification Code Term Level
    15.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003555 Asthma bronchial LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-000188-15 Sponsor Protocol Number: AL1402ac Start Date*: 2017-01-09
    Sponsor Name:Allergopharma GmbH & Co. KG
    Full Title: A multicenter randomized double-blind placebo-controlled clinical trial for evaluation of efficacy and safety of specific immunotherapy with an aluminium hydroxide-adsorbed allergoid preparation o...
    Medical condition: allergic bronchial asthma and allergic rhinitis or rhinoconjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10039097 Rhinoconjunctivitis LLT
    20.0 100000004855 10001705 Allergic asthma LLT
    20.0 100000004855 10001723 Allergic rhinitis LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: PL (Completed) LT (Completed) DE (Completed) ES (Completed) LV (Completed) AT (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2010-022458-18 Sponsor Protocol Number: 205.425 Start Date*: 2011-05-23
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: A phase II randomised, double-blind, placebo-controlled incomplete cross-over trial with 4-week treatment periods to evaluate efficacy and safety of tiotropium inhalation solution (doses of 1.25 μg...
    Medical condition: Moderate persistent asthma in children 6 to 11 years old
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003555 Asthma bronchial LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) LV (Completed) LT (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2007-000135-26 Sponsor Protocol Number: 2006-04-DOS-2 Start Date*: 2007-06-08
    Sponsor Name:Hexal AG
    Full Title: Double-blind, double-dummy, multi-center, randomized parallel group trial to demonstrate therapeutic equivalence of Salmeterol/Fluticasone MDI HEXAL (25 µg/50 µg per actuation) versus SeretideTM 50...
    Medical condition: Persistent, moderate asthma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003555 Asthma bronchial LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: LT (Completed)
    Trial results: View results
    EudraCT Number: 2007-000134-39 Sponsor Protocol Number: 2006-03-DOS-1 Start Date*: 2007-04-19
    Sponsor Name:Hexal AG
    Full Title: Double-blind, double-dummy, multi-center, randomized parallel group trial to demonstrate therapeutic equivalence of Salmeterol/Fluticasone MDI HEXAL (25 µg/125 µg per actuation) versus SeretideTM 1...
    Medical condition: persistent moderate asthma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003555 Asthma bronchial LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: LT (Completed) HU (Completed) PL (Ongoing)
    Trial results: View results
    EudraCT Number: 2006-003103-39 Sponsor Protocol Number: AR003 Start Date*: 2007-04-19
    Sponsor Name:University of Glasgow & Greater Glasgow Health Board
    Full Title: Effect of statins on asthma control and airway inflammation in smokers with asthma
    Medical condition: Chronic Asthma (smokers),COPD.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10003553 Asthma LLT
    9.1 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-001532-19 Sponsor Protocol Number: 206821 Start Date*: 2018-09-11
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A randomised open-label study to compare the effectiveness of the fixed dose combination of FF/UMEC/VI (using the Connected Inhaler System) with the combination of FP/SAL plus tiotropium (without t...
    Medical condition: Inadequately controlled asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-001029-84 Sponsor Protocol Number: AL0702rB Start Date*: 2007-08-30
    Sponsor Name:Allergopharma Joachim Ganzer KG
    Full Title: A multicentre randomised, placebo-controlled, double-blind pivotal clinical trial for the evaluation of safety and efficacy of specific of immunotherapy with an aluminium hydroxide-adsorbed hypoall...
    Medical condition: ICD classification code: J45.0 and J30.1
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039085 Rhinitis allergic LLT
    9.1 10001705 Allergic asthma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2018-004381-33 Sponsor Protocol Number: CQAW039A2127 Start Date*: 2019-12-11
    Sponsor Name:Novartis Pharma AG
    Full Title: Randomized, subject and investigator blinded, placebo-controlled study to demonstrate the anti-inflammatory effect of fevipiprant (QAW039) in moderate-severe asthma patients with high sputum and...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) FR (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) BE (Completed)
    Trial results: View results
    EudraCT Number: 2009-017223-25 Sponsor Protocol Number: FLT3507 Start Date*: 2010-04-01
    Sponsor Name:Mundipharma Research Ltd
    Full Title: A double blind, double dummy, randomised, multicentre, two arm parallel group study to assess the efficacy and safety of FlutiForm® pMDI 125/5 µg (2 puffs bid) vs Symbicort® Turbohaler® 200/6 µg (2...
    Medical condition: Asthma bronchial
    Disease: Version SOC Term Classification Code Term Level
    12.1 10003555 Asthma bronchial LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed) HU (Completed) BG (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Apr 04 06:07:52 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA